HIPRA
Avda. la Selva. 135, 17170 Amer (Girona), Spain
Phone.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

HIPRA receives European Commission marketing authorisation for its COVID-19 vaccine adapted to the XFG.1.1 variant

The authorisation includes two ready-to-use presentations: a single-dose vial and, for the first time, a pre-filled syringe

Girona, July 31, 2026 – HIPRA has received **European Commission marketing authorisation for its recombinant protein adjuvanted COVID-19 vaccine**[1], BIMERVAX®, adapted to the XFG.1.1 variant.

The updated vaccine is authorised for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older. This is **the third adaptation of HIPRA's COVID-19 vaccine** and follows the positive opinion adopted by the **European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)** at its July 2026 meeting.

The XFG.1.1 adapted vaccine has been updated in line with the recommendations issued by the European Medicines Agency Task Force (ETF), which **selected the XFG variant as the preferred target for the 2026/2027 vaccination campaign**. The recommendation was based on the current epidemiological situation and available evidence supporting broader protection against circulating JN.1-lineage variants[2].

"This European Commission authorisation enables HIPRA to provide an updated recombinant protein vaccine option for the 2026/2027 vaccination campaign. It also reflects HIPRA's continued capacity to adapt our COVID-19 vaccine to the evolution of SARS-CoV-2 while maintaining a consistent manufacturing platform", said **Carles Fàbrega, Managing Director Human Health at HIPRA.**

Two ready-to-use presentations

HIPRA's COVID-19 vaccine already offers a ready-to-use **single-dose vial,** and, **for the first time** it is also available in a **pre-filled syringe (PFS)**. These two ready-to-use presentations offer **healthcare professionals different presentation** options according to clinical practice.

BIMERVAX® has been **developed 100% in Europe** and is manufactured at **HIPRA's facilities in the province of Girona (Spain),** where key stages of the vaccine's life cycle are integrated, including research and development, industrial-scale manufacturing, quality control, regulatory activities and final batch release, under a fully integrated model.

HIPRA
Avda. la Selva. 135, 17170 Amer (Girona), Spain
Phone.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

An additional option for COVID-19 prevention

COVID-19 virus continues to circulate across Europe and worldwide, remaining a burden on healthcare systems. As a result, vaccination campaigns play an important role in protecting the population.

Stijn Hollemeersch, Medical Affairs Director Human Health at HIPRA, adds: "We are proud to contribute another updated vaccine option that supports vaccination strategies around the world, underlining the importance of vaccination as one of the most effective ways to protect people against COVID-19 and strengthen public health".

With this authorisation, the pharmaceutical biotechnology company adds a new recombinant protein vaccine option for the 2026/2027 vaccination campaign, by combining scientific expertise, manufacturing capabilities and continuous adaptation to the evolving epidemiological landscape.

About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention in animal and human health (One Health), with a wide range of highly innovative vaccines and an advanced diagnostic service. With its claim **"Building immunity for a healthier world"**, HIPRA reaffirms its commitment to contributing solutions that improve global health.

The company has a strong international presence with **40 subsidiaries, 3 R&D centers and 6 production facilities** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network keeps commercial channels open in nearly 100 additional countries, thus covering all five continents.

Research and development are at the core of its expertise. HIPRA invests **around the 15% of its annual revenue to R&D activities and infrastructure**, focused on the creation and application of the latest scientific advances for the development of innovative vaccines of the highest quality. HIPRA has a portfolio of vaccines based on different technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add further value to its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Press contacts
Irene Calle – icalle@harmon.es – M. 609 873 052
José María Nieto – jnieto@harmon.es – M. 689 186 062
Sara Mancebo – smancebo@harmon.es – M. 628 388 791

References

HIPRA
Avda. la Selva. 135, 17170 Amer (Girona), Spain
Phone.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

1. European Commission. Union Register of medicinal products for human use [Internet]. Brussels: European Commission; [cited 2026 July 31]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1709.htm
2. European Medicines Agency (EMA). ETF recommends updating COVID-19 vaccines to target XFG variant [Internet]. Amsterdam: European Medicines Agency; 2026 May 29 [cited 2026 Jul 6]. Available from: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-xfg-variant